Show simple item record

dc.contributor.authorFerguson, Janice E
dc.contributor.authorSchor, Ana M
dc.contributor.authorHowell, Anthony
dc.contributor.authorFerguson, M W
dc.date.accessioned2010-08-18T09:29:15Z
dc.date.available2010-08-18T09:29:15Z
dc.date.issued1990-02
dc.identifier.citationTenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. 1990, 42 (3):199-207 Differentiationen
dc.identifier.issn0301-4681
dc.identifier.pmid1692795
dc.identifier.doi10.1111/j.1432-0436.1990.tb00762.x
dc.identifier.urihttp://hdl.handle.net/10541/109811
dc.description.abstractTenascin is a novel extracellular matrix glycoprotein which appears to have a major role in tissue development. Previous studies have stated that tenascin is absent from the normal human, rat and mouse breast, its distribution being restricted to embryonic and malignant mammary tissues. No previous studies have investigated tenascin distribution as a function of the normal menstrual cycle. Therefore this study addresses the cyclical appearance of tenascin in the normal breast and associated changes in distribution in preinvasive cancer (carcinoma-in-situ) and invasive infiltrating ductal carcinoma. Tenascin is present in the normal human adult mammary gland, principally in the basement membrane, sub-basement-membrane zone and delimiting layer of fibroblasts around the ductules. Both the distribution and quantity of tenascin change during the menstrual cycle. In carcinoma-in-situ (preinvasive cancer) tenascin is present in the attenuated basement membrane/sub-basement-membrane zone around the expanded ductules and in small amounts in the stroma. In infiltrating ductal carcinoma, tenascin is absent from the remnants of the basement membrane and sub-basement-membrane zone but greatly increased in the adjacent intralobular and interlobular stroma. Therefore, if tenascin is used as a basement membrane/sub-basement-membrane marker for distinguishing carcinoma-in-situ from invasive ductal carcinoma, the time of the menstrual cycle is of importance in interpreting the biopsy appearance. This study suggests that the optimal time for biopsy is between weeks 3 and 4 of the cycle, to avoid confusion between the normal low levels of tenascin (due to hormonal status) and those due to microinvasive disease.(ABSTRACT TRUNCATED AT 250 WORDS)
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Invasivenessen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBreast
dc.subject.meshBreast Neoplasms
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating
dc.subject.meshCell Adhesion Molecules, Neuronal
dc.subject.meshFemale
dc.subject.meshFluorescent Antibody Technique
dc.subject.meshHumans
dc.subject.meshMenstrual Cycle
dc.subject.meshNeoplasm Invasiveness
dc.subject.meshTenascin
dc.titleTenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Withington, Manchester, England.en
dc.identifier.journalDifferentiationen
html.description.abstractTenascin is a novel extracellular matrix glycoprotein which appears to have a major role in tissue development. Previous studies have stated that tenascin is absent from the normal human, rat and mouse breast, its distribution being restricted to embryonic and malignant mammary tissues. No previous studies have investigated tenascin distribution as a function of the normal menstrual cycle. Therefore this study addresses the cyclical appearance of tenascin in the normal breast and associated changes in distribution in preinvasive cancer (carcinoma-in-situ) and invasive infiltrating ductal carcinoma. Tenascin is present in the normal human adult mammary gland, principally in the basement membrane, sub-basement-membrane zone and delimiting layer of fibroblasts around the ductules. Both the distribution and quantity of tenascin change during the menstrual cycle. In carcinoma-in-situ (preinvasive cancer) tenascin is present in the attenuated basement membrane/sub-basement-membrane zone around the expanded ductules and in small amounts in the stroma. In infiltrating ductal carcinoma, tenascin is absent from the remnants of the basement membrane and sub-basement-membrane zone but greatly increased in the adjacent intralobular and interlobular stroma. Therefore, if tenascin is used as a basement membrane/sub-basement-membrane marker for distinguishing carcinoma-in-situ from invasive ductal carcinoma, the time of the menstrual cycle is of importance in interpreting the biopsy appearance. This study suggests that the optimal time for biopsy is between weeks 3 and 4 of the cycle, to avoid confusion between the normal low levels of tenascin (due to hormonal status) and those due to microinvasive disease.(ABSTRACT TRUNCATED AT 250 WORDS)


This item appears in the following Collection(s)

Show simple item record